Facts You Need to Understand Kintara Therapeutics Stock

By Susan Ramirez • Wednesday, November 30 10:16 • Permanent Link

Small-cap Healthcare company Kintara Therapeutics has moved -5.4% so far today on a volume of 974,027, compared to its average of 248,903. In contrast, the S&P 500 index moved -0.2%

The one analyst following Kintara Therapeutics has given it a rating of hold and a target price of $150 per share. Now, the company is currently trading -96.25% away from its target price.

If you are considering an investment in KTRA, you'll want to know the following:

Kintara Therapeutics's Graham number (a purchase price with a built-in margin of safety) is $5.13, which is 9.8% away from its current price
Kintara Therapeutics has moved -81.9% over the last year, and the S&P 500 logged a change of -12.3%
Based on its trailing earning per share of -0.64, Kintara Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -8.8 while the S&P 500 average is 15.97
KTRA has a forward P/E ratio of -0.5 based on its forward 12 month price to earnings (Eps) is $-12.43 per share
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients.
Based in San Diego, the company has 3 full time employees and a market cap of $9,097,309.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.